Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy

Autor: Mazzaro, Cesare, Dal Maso, Luigino, Mauro, Endri, Visentini, Marcella, Tonizzo, Maurizio, Gattei, Valter, Andreone, Pietro, Pozzato, Gabriele

Publikováno v: In Autoimmunity Reviews August 2020 19(8)

Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection

Autor: Spengler, Ulrich

Publikováno v: In Pharmacology and Therapeutics March 2018 183:118-126

Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

Autor: Haitham A. Azeem, Ashraf M. Alkabeer, Ali Sobhy Mohammed, Amira Ahmed Hussein

Publikováno v: Egyptian Liver Journal, Vol 11, Iss 1, Pp 1-8 (2021)

Abstract Background Hepatitis B virus (HBV) may reactivate when treating chronic hepatitis C (CHC) with direct-acting antivirals (DAA). We aimed to investigate the risk of HBV infection and reactivation during DAA therapy by performing a prospective

Externí odkaz: https://doaj.org/article/bc78e18200014ba4ab727c4eddfba21f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).

Autor: Abdul Massih S; Division of Clinical Pharmacology & Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Eke AC; Division of Clinical Pharmacology & Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Division of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Publikováno v: Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2022 Nov; Vol. 20 (11), pp. 1413-1424. Date of Electronic Publication: 2022 Sep 20.